InjuryBoard Houston Archives

• Arcoxia, that's a "No-Go" per the FDA

  Tiffany Farr | April 27, 2007 4:45 PM | 0 Comments
  Category: FDA & Prescription Drugs

  Arcoxia, Merck's latest in its line of Cox-2 inhibitors, has received a non-approval letter from the FDA. Currently on the market in 63 countries, Arcoxia has been marketed for arthritis relief and currently contributes roughly $265 million a year in sales for Merck. The FDA has said that in order for Arcoxia to be approved in the United States, Merck "needs to provide more test results...

• Merck's Vioxx successor being reviewed by FDA

  Lindsay Bauer | April 20, 2007 3:20 PM | 0 Comments
  Category: Miscellaneous

  Merck has created a successor to its now defunct drug Vioxx. The new nonsteroidal anti-inflammatory drug (NSAID) is called Arcoxia. Like Vioxx, Arcoxia is a Cox-2 inhibitor and was developed to treat osteoarthritis, but be gentler on the stomach then other drugs. On Tuesday, April 10, 2007 FDA advisers discussed the safety of Arcoxia as they attempted to determine if the new drug should be...

• Environmentalists win battle over EPA

  Lindsay Bauer | April 13, 2007 8:54 AM | 0 Comments
  Category: Miscellaneous

  On April 2, 2007 a major battle was won on behalf of Massachusetts and environmentalists everywhere. The case of Massachusetts v. the Environmental Protection Agency ruled in a 5-4 decision that the federal government was wrong to ignore its responsibility to regulate carbon dioxide emission from cars and trucks. It is hoped that this ruling will lead to much needed federal action to slow...

• Zelnorm Recall

  Vickye Young | April 03, 2007 3:19 PM | 0 Comments
  Category: FDA & Prescription Drugs

  At the request of the US Food and Drug Administration, Zelnorm (tegaserod maleate), an irritable bowel syndrome drug manufactured by Swiss drugmaker Novartis Pharmaceuticals Corporation, has been recalled.Approved in 2002 by the FDA, Zelnorm was prescribed to women for short-term treatment of irritable bowel syndrome with constipation, and in 2004 for men and women younger than 65 with chronic...